Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. Read more about Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Read more about Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Read more about Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Read more about Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Read more about Characterization of human IgG antimouse antibody in patients with B-cell malignancies.
Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Read more about Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies.
A transcriptional progression model for head and neck cancer. Read more about A transcriptional progression model for head and neck cancer.
The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Read more about The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Read more about Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Read more about A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
